You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

APRESOLINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Apresoline patents expire, and what generic alternatives are available?

Apresoline is a drug marketed by Novartis and is included in two NDAs.

The generic ingredient in APRESOLINE is hydralazine hydrochloride; hydrochlorothiazide. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for APRESOLINE?
  • What are the global sales for APRESOLINE?
  • What is Average Wholesale Price for APRESOLINE?
Summary for APRESOLINE
Drug patent expirations by year for APRESOLINE
Recent Clinical Trials for APRESOLINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medical College of WisconsinN/A
University of CincinnatiPhase 2
Vanderbilt University Medical CenterPhase 2

See all APRESOLINE clinical trials

US Patents and Regulatory Information for APRESOLINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis APRESOLINE hydralazine hydrochloride INJECTABLE;INJECTION 008303-003 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis APRESOLINE hydralazine hydrochloride TABLET;ORAL 008303-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis APRESOLINE hydralazine hydrochloride TABLET;ORAL 008303-004 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis APRESOLINE hydralazine hydrochloride TABLET;ORAL 008303-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis APRESOLINE-ESIDRIX hydralazine hydrochloride; hydrochlorothiazide TABLET;ORAL 012026-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis APRESOLINE hydralazine hydrochloride TABLET;ORAL 008303-005 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.